UEG Week: Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes

Contributed by: PR Newswire

Tags

UEG-Week

More Like This

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

ESGE Days 2026: Endoscopic procedure associated with greater short-term weight loss than oral semaglutide, study finds

PR Newswire associated0

Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management

ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

PR Newswire associated0

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows

PR Newswire associated0

Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD